Pamrevlumab
In this article we will explore in depth the topic of Pamrevlumab, its impact on today's society and its relevance in different areas. Throughout history, Pamrevlumab has been a topic of great interest and research, with multiple perspectives and approaches that have contributed to the understanding and development of new ideas. From its influence on the economy, culture and politics, to its impact on people's daily lives, Pamrevlumab has proven to be a multidimensional issue that deserves to be analyzed and discussed. Through exhaustive analysis, this article will seek to provide a clear and comprehensive view on Pamrevlumab, offering readers a deeper and more meaningful understanding of its importance today.
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CTGF |
| Clinical data | |
| Other names | FG-3019 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10018N1718O2086S48 |
| Molar mass | 147050.38 g·mol−1 |
Pamrevlumab (INN;[1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.[2]
This drug was developed by FibroGen, Inc.[3]
References
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- ^ Sgalla G, Franciosa C, Simonetti J, Richeldi L (August 2020). "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis". Expert Opinion on Investigational Drugs. 29 (8): 771–777. doi:10.1080/13543784.2020.1773790. PMID 32447983. S2CID 218873298.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |